UNICHEM LAB | NEULAND LABS | UNICHEM LAB/ NEULAND LABS |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -47.5 | 48.7 | - | View Chart |
P/BV | x | 1.2 | 3.7 | 31.7% | View Chart |
Dividend Yield | % | 1.2 | 0.1 | 1,210.5% |
![]() ![]() |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
UNICHEM LAB Mar-19 |
NEULAND LABS Mar-20 |
UNICHEM LAB/ NEULAND LABS |
5-Yr Chart Click to enlarge
|
||
High | Rs | 292 | 754 | 38.7% | |
Low | Rs | 182 | 247 | 73.6% | |
Sales per share (Unadj.) | Rs | 167.7 | 594.5 | 28.2% | |
Earnings per share (Unadj.) | Rs | -3.6 | 12.6 | -28.7% | |
Cash flow per share (Unadj.) | Rs | 5.9 | 37.0 | 16.1% | |
Dividends per share (Unadj.) | Rs | 4.00 | 2.00 | 200.0% | |
Dividend yield (eoy) | % | 1.7 | 0.4 | 422.3% | |
Book value per share (Unadj.) | Rs | 372.3 | 553.4 | 67.3% | |
Shares outstanding (eoy) | m | 70.38 | 12.83 | 548.6% | |
Bonus/Rights/Conversions | ESOP | - | - | ||
Price / Sales ratio | x | 1.4 | 0.8 | 167.9% | |
Avg P/E ratio | x | -65.3 | 39.6 | -164.8% | |
P/CF ratio (eoy) | x | 39.9 | 13.5 | 295.0% | |
Price / Book Value ratio | x | 0.6 | 0.9 | 70.4% | |
Dividend payout | % | -110.2 | 15.8 | -695.9% | |
Avg Mkt Cap | Rs m | 16,680 | 6,421 | 259.8% | |
No. of employees | `000 | 2.6 | 1.3 | 203.0% | |
Total wages/salary | Rs m | 2,393 | 1,236 | 193.7% | |
Avg. sales/employee | Rs Th | 4,535.2 | 5,949.4 | 76.2% | |
Avg. wages/employee | Rs Th | 919.8 | 963.8 | 95.4% | |
Avg. net profit/employee | Rs Th | -98.2 | 126.4 | -77.7% |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 11,801 | 7,627 | 154.7% | |
Other income | Rs m | 984 | 39 | 2,533.1% | |
Total revenues | Rs m | 12,785 | 7,666 | 166.8% | |
Gross profit | Rs m | -835 | 1,019 | -81.9% | |
Depreciation | Rs m | 674 | 313 | 215.4% | |
Interest | Rs m | 75 | 216 | 34.9% | |
Profit before tax | Rs m | -600 | 529 | -113.3% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 1 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -343 | 367 | -93.6% | |
Profit after tax | Rs m | -256 | 162 | -157.7% | |
Gross profit margin | % | -7.1 | 13.4 | -53.0% | |
Effective tax rate | % | 57.3 | 69.4 | 82.6% | |
Net profit margin | % | -2.2 | 2.1 | -101.9% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 20,384 | 5,152 | 395.7% | |
Current liabilities | Rs m | 5,029 | 3,576 | 140.6% | |
Net working cap to sales | % | 130.1 | 20.7 | 629.9% | |
Current ratio | x | 4.1 | 1.4 | 281.4% | |
Inventory Days | Days | 105 | 105 | 99.7% | |
Debtors Days | Days | 135 | 91 | 148.4% | |
Net fixed assets | Rs m | 9,023 | 3,969 | 227.4% | |
Share capital | Rs m | 141 | 129 | 109.1% | |
"Free" reserves | Rs m | 26,058 | 6,971 | 373.8% | |
Net worth | Rs m | 26,199 | 7,100 | 369.0% | |
Long term debt | Rs m | 0 | 774 | 0.0% | |
Total assets | Rs m | 31,496 | 12,310 | 255.9% | |
Interest coverage | x | -7.0 | 3.5 | -202.0% | |
Debt to equity ratio | x | 0 | 0.1 | 0.0% | |
Sales to assets ratio | x | 0.4 | 0.6 | 60.5% | |
Return on assets | % | -0.6 | 3.1 | -18.7% | |
Return on equity | % | -1.0 | 2.3 | -42.7% | |
Return on capital | % | -2.0 | 9.5 | -21.1% | |
Exports to sales | % | 69.4 | 0 | - | |
Imports to sales | % | 0 | 0 | - | |
Exports (fob) | Rs m | 8,188 | NA | - | |
Imports (cif) | Rs m | NA | NA | - | |
Fx inflow | Rs m | 8,188 | 5,187 | 157.9% | |
Fx outflow | Rs m | 596 | 1,593 | 37.4% | |
Net fx | Rs m | 7,592 | 3,594 | 211.2% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | -3,278 | 573 | -571.6% | |
From Investments | Rs m | -2,860 | -487 | 587.5% | |
From Financial Activity | Rs m | -24 | -55 | 44.2% | |
Net Cashflow | Rs m | -4,690 | 33 | -14,387.1% |
Indian Promoters | % | 50.1 | 36.3 | 138.1% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 15.1 | 63.7 | 23.7% | |
FIIs | % | 3.0 | 0.0 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 31.7 | 63.7 | 49.7% | |
Shareholders | 20,176 | 12,705 | 158.8% | ||
Pledged promoter(s) holding | % | 0.0 | 0.0 | - |
Compare UNICHEM LAB With: JUBILANT PHARMOVA PANACEA BIOTECH WOCKHARDT ABBOTT INDIA FRESENIUS KABI ONCO.
Compare UNICHEM LAB With: MYLAN (US) ADCOCK INGRAM (S. Africa) ACTAVIS (US) TEVA PHARMA (Israel)
Indian share markets witnessed buying interest during closing hours and ended today's volatile session higher.
For the quarter ended December 2020, NEULAND LABS has posted a net profit of Rs 267 m (up 141.5% YoY). Sales on the other hand came in at Rs 2 bn (up 20.5% YoY). Read on for a complete analysis of NEULAND LABS's quarterly results.
Here's an analysis of the annual report of NEULAND LABS for 2019-20. It includes a full income statement, balance sheet and cash flow analysis of NEULAND LABS. Also includes updates on the valuation of NEULAND LABS.
For the quarter ended June 2019, UNICHEM LAB has posted a net profit of Rs 5 m (up 102.2% YoY). Sales on the other hand came in at Rs 2 bn (up 15.4% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
Here's an analysis of the annual report of UNICHEM LAB for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of UNICHEM LAB. Also includes updates on the valuation of UNICHEM LAB.
For the quarter ended March 2019, UNICHEM LAB has posted a net profit of Rs 37 m (up 31.7% YoY). Sales on the other hand came in at Rs 3 bn (up 35.1% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.
More Views on NewsLast time the smallcap index crossed 19k a big correction followed. Here's what makes it different this time.
In this video, I'll show you how to get started on the path to daily trading profits.
In this episode, ace trader Brijesh Bhatia talks to us about the best investments of 2021, his profitable trading system, and much more.
An Indian company founded three decades ago in a garage caught my attention...
More